A H Sarris

2.4k total citations
46 papers, 1.6k citations indexed

About

A H Sarris is a scholar working on Pathology and Forensic Medicine, Oncology and Molecular Biology. According to data from OpenAlex, A H Sarris has authored 46 papers receiving a total of 1.6k indexed citations (citations by other indexed papers that have themselves been cited), including 24 papers in Pathology and Forensic Medicine, 22 papers in Oncology and 12 papers in Molecular Biology. Recurrent topics in A H Sarris's work include Lymphoma Diagnosis and Treatment (24 papers), Chronic Lymphocytic Leukemia Research (8 papers) and Cancer Treatment and Pharmacology (8 papers). A H Sarris is often cited by papers focused on Lymphoma Diagnosis and Treatment (24 papers), Chronic Lymphocytic Leukemia Research (8 papers) and Cancer Treatment and Pharmacology (8 papers). A H Sarris collaborates with scholars based in United States, Canada and Greece. A H Sarris's co-authors include Fernando Cabanillas, Jorge Romaguera, Peter McLaughlin, Fredrick B. Hagemeister, George E. Palade, F Swan, Anas Younes, Maria Alma Rodriguez, O. Pate and William Pugh and has published in prestigious journals such as Journal of Biological Chemistry, The Journal of Experimental Medicine and Journal of Clinical Oncology.

In The Last Decade

A H Sarris

46 papers receiving 1.5k citations

Peers

Countries citing papers authored by A H Sarris

Since Specialization

Citations

This map shows the geographic impact of A H Sarris's research. It shows the number of citations coming from papers published by authors working in each country. You can also color the map by specialization and compare the number of citations received by A H Sarris with the expected number of citations based on a country's size and research output (numbers larger than one mean the country cites A H Sarris more than expected).

Fields of papers citing papers by A H Sarris

Since Specialization

Physical SciencesHealth SciencesLife SciencesSocial Sciences

This network shows the impact of papers produced by A H Sarris. Nodes represent research fields, and links connect fields that are likely to share authors. Colored nodes show fields that tend to cite the papers produced by A H Sarris. The network helps show where A H Sarris may publish in the future.

Co-authorship network of co-authors of A H Sarris

This figure shows the co-authorship network connecting the top 25 collaborators of A H Sarris. A scholar is included among the top collaborators of A H Sarris based on the total number of citations received by their joint publications. Widths of edges represent the number of papers authors have co-authored together. Node borders signify the number of papers an author published with A H Sarris. A H Sarris is excluded from the visualization to improve readability, since they are connected to all nodes in the network.

All Works

Sort: Min cites: Since: Top N: Style:

20 of 20 papers shown

#	Work	Indexed citations
1	Primary cutaneous non-Hodgkin’s lymphoma with aggressive histology: inferior outcome is associated with peripheral T-cell type and elevated lactate dehydrogenase, but not extent of cutaneous involvement 2002 ·Annals of Oncology ·Carlo Visco, L. Jeffrey Medeiros, Dana Jones, Terry Smith, Maria Alma Rodriguez, Peter McLaughlin, Jorge Romaguera, Fernando Cabanillas, A H Sarris	6
2	Phase II study of a high-dose ifosfamide-based chemotherapy regimen with growth factor rescue in recurrent aggressive NHL. High response rates and limited toxicity, but limited impact on long-term survival 2001 ·Bone Marrow Transplantation ·Koen van Besien, A Rodríguez, Sandra C. Tomany, Anas Younes, Michèle L. Donato, A H Sarris, Sergio Giralt, Rakesh Mehra, Börje S. Andersson, James Gajewski, Richard E. Champlin, Fernando Cabanillas	10
3	Liposomal vincristine in relapsed non-Hodgkin's lymphomas: Early results of an ongoing phase II trial 2000 ·Annals of Oncology ·A H Sarris, Frederick Hagemeister, Jorge Romaguera, Maritza Rodríguez, Peter McLaughlin, Apostolia M. Tsimberidou, L. Jeffrey Medeiros, Barry I. Samuels, O. Pate, (unknown), Hagop M. Kantarjian, (unknown), Fernando Cabanillas	109
4	Allogeneic stem cell transplantation with fludarabine-based, less intensive conditioning regimens as adoptive immunotherapy in advanced Hodgkin's disease 2000 ·Bone Marrow Transplantation ·P Anderlini, Sergio Giralt, Börje S. Andersson, Naoto T. Ueno, I. Khouri, Sandra Acholonu, A Cohen, M Körbling, John T. Manning, Jorge Romaguera, A H Sarris, (unknown), Frederick Hagemeister, Peter McLaughlin, Fernando Cabanillas, RE Champlin	66
5	Cytokine expression patterns distinguish HIV associated skin diseases 2000 ·Experimental Dermatology ·Joan Breuer-McHam, (unknown), A H Sarris, Madeleine Duvic	16
6	Infusional Vinorelbine in Relapsed or Refractory Lymphomas 2000 ·Leukemia & lymphoma ·A H Sarris, Amanda Psyrri, Fredrick B. Hagemeister, Jorge Romaguera, Peter McLaughlin, (unknown), Carlos Bachier, Anas Younes, (unknown), (unknown), L. Jeffrey Medeiros, Barry I. Samuels, Laurel M. Adams, Fernando Cabanillas	8
7	Interleukin-10 levels are often elevated in serum of adults with Hodgkin's disease and are associated with inferior failure-free survival 1999 ·Annals of Oncology ·A H Sarris, K. O. Kliche, (unknown), A. Preti, Søren M. Bentzen, Clotilde M. Jackow, Osvaldo Daniel Messina, William Pugh, Fredrick B. Hagemeister, Peter McLaughlin, Maria Alma Rodriguez, Jorge Romaguera, Herbert A. Fritsche, Thomas E. Witzig, Madeleine Duvic, M Andreeff, Fernando Cabanillas	132
8	Use of the International Prognostic Index and the Tumor Score to Detect Poor-Risk Patients with Primary Mediastinal Large B-Cell Lymphoma: A Study of 37 Previously Untreated Patients 1998 ·Leukemia & lymphoma ·Jorge Romaguera, (unknown), Lenore L. Carias, Fredrick B. Hagemeister, Peter McLaughlin, Maria Alma Rodriguez, A H Sarris, Anas Younes, A. Preti, Carlos Bachier, (unknown), Fernando Cabanillas	17
9	Ninety-Six-Hour Paclitaxel Infusion with Mitoxantrone and Ifosfamide/Mesna and Consolidation with ESHAP for Refractory and Relapsed Non-Hodgkin's Lymphoma 1998 ·Leukemia & lymphoma ·Jorge Romaguera, Fredrick B. Hagemeister, Peter McLaughlin, Maria Alma Rodriguez, Carlos Bachier, H. Alejandro Preti, A H Sarris, Damien C. Weber, Anas Younes, Fernando Cabanillas	3
10	Cyclosporin A does not reverse clinical resistance to paclitaxel in patients with relapsed non-Hodgkin's lymphoma. 1996 ·Journal of Clinical Oncology ·A H Sarris, Anas Younes, Peter McLaughlin, Dennis W. Moore, Frederick Hagemeister, F Swan, Maria Alma Rodriguez, Jorge Romaguera, L North, Paul Mansfield, (unknown), (unknown), Fernando Cabanillas	32
11	Macrophage-stimulating protein, a ligand for the RON receptor protein tyrosine kinase, suppresses myeloid progenitor cell proliferation and synergizes with vascular endothelial cell growth factor and members of the chemokine family 1996 ·Annals of Hematology ·Hal E. Broxmeyer, Stephanie Cooper, (unknown), Li Lu, A H Sarris, (unknown), Ming‐Shi Chang, David B. Donner, Edward J. Leonard	25
12	Preliminary experience with paclitaxel for the treatment of relapsed and refractory Hodgkin's disease 1996 ·Annals of Oncology ·Anas Younes, Fernando Cabanillas, Peter W. McLaughlin, Frederick Hagemeister, Charles M. Farber, A H Sarris, O. Pate, Jane Myers, C. Portlock	6
13	Cyclosporin plus doxorubicin, vincristine and etoposide in the treatment of refractory non-Hodgkin's lymphoma: A phase II study 1995 ·Clinical Oncology ·David Moore, F Swan, J. Yau, María Carmen Rodriguez, Peter McLaughlin, A H Sarris, Jorge Romaguera, Anas Younes, (unknown), Fernando Cabanillas	5
14	Human chemokines: enhancement of specific activity and effects in vitro on normal and leukemic progenitors and a factor-dependent cell line and in vivo in mice 1995 ·Annals of Hematology ·H E Broxmeyer, Scott Cooper, Nancy Hague, L. Benninger, A H Sarris, Kenneth Cornetta, Saroj Vadhan‐Raj, Paul C. Hendrie, Charlie Mantel	58
15	Human chemokines: enhancement of specific activity and effects in vitro on normal and leukemic progenitors and a factor-dependent cell line and in vivo in mice 1995 ·Annals of Hematology ·H E Broxmeyer, Stephanie Cooper, Nancy Hague, L. Benninger, A H Sarris, Kenneth Cornetta, Saroj Vadhan‐Raj, Paul C. Hendrie, Charlie Mantel	9
16	Testicular lymphoma: late relapses and poor outcome despite doxorubicin-based therapy. 1995 ·Journal of Clinical Oncology ·Nikolaos Touroutoglou, Meletios Α. Dimopoulos, Ahmed Younes, (unknown), William Pugh, James D. Cox, Fernando Cabanillas, A H Sarris	75
17	Three-hour paclitaxel infusion in patients with refractory and relapsed non-Hodgkin's lymphoma. 1995 ·Journal of Clinical Oncology ·Anas Younes, A H Sarris, A. Melnyk, Jorge Romaguera, Peter McLaughlin, F Swan, Maria Alma Rodriguez, Fredrick B. Hagemeister, David H. Moore, L North	34
18	Intensive conventional-dose chemotherapy for stage IV low-grade lymphoma: High remission rates and reversion to negative of peripheral blood bcl-2 rearrangement 1994 ·Annals of Oncology ·Peter McLaughlin, (unknown), F Swan, Fernando Cabanillas, Jorge Romaguera, Maria Alma Rodriguez, (unknown), O. Pate, A H Sarris, Anas Younes	42
19	Human interferon-inducible protein 10: expression and purification of recombinant protein demonstrate inhibition of early human hematopoietic progenitors. 1993 ·The Journal of Experimental Medicine ·A H Sarris, H E Broxmeyer, Urs Wirthmueller, Nicos Karasavvas, (unknown), Lu Li, James G. Krueger, Jeffrey V. Ravetch	87
20	Immunofluorescent detection of erythrocyte sialoglycoprotein antigens on murine erythroid cells. 1982 ·The Journal of Cell Biology ·A H Sarris, George E. Palade	12

Rankless uses publication and citation data sourced from OpenAlex, an open and comprehensive bibliographic database. While OpenAlex provides broad and valuable coverage of the global research landscape, it—like all bibliographic datasets—has inherent limitations. These include incomplete records, variations in author disambiguation, differences in journal indexing, and delays in data updates. As a result, some metrics and network relationships displayed in Rankless may not fully capture the entirety of a scholar's output or impact.

Explore authors with similar magnitude of impact